Audiomedica.com
Genomically Targeted Therapy Delays Advanced Breast Cancer Progression
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:00:06
- Mas informaciones
Informações:
Sinopsis
MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestrant in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast …Fabrice André ESMO 2018 AJO Genomic Breast Cancer Targeting
